Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
0.5500
-0.0290 (-5.01%)
At close: May 13, 2026, 4:00 PM EDT
0.5339
-0.0161 (-2.93%)
After-hours: May 13, 2026, 7:39 PM EDT
Silexion Therapeutics Employees
As of December 31, 2025, Silexion Therapeutics had 14 total employees, including 13 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
14
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$850,857
Market Cap
1.83M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 14 | 0 | - | 13 | 1 |
| Dec 31, 2024 | 14 | - | - | 11 | 3 |
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 47 |
| HCW Biologics | 36 |
| Scinai Immunotherapeutics | 31 |
| AIM ImmunoTech | 21 |
| Soligenix | 14 |
| Biodexa Pharmaceuticals | 11 |
| Artelo Biosciences | 7 |
| Adial Pharmaceuticals | 5 |
SLXN News
- 12 hours ago - Silexion Therapeutics initiates GMP clinical batch manufacturing of SIL204 - TheFly
- 17 hours ago - Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center - GlobeNewsWire
- 15 days ago - Silexion Therapeutics submits SIL204 clinical trial application to Germany - TheFly
- 15 days ago - Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer - GlobeNewsWire
- 7 weeks ago - Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204 - TheFly
- 7 weeks ago - Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewsWire
- 2 months ago - Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Silexion Therapeutics urges shareholders to vote ahead of EGM - TheFly